Dongliang Lin serves as Executive at CASI Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Dongliang Lin has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Nov 13, 2018 involved exercising options for 1,699,753 shares valued at $2.9M.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Nov 13, 2018 | CASI | $2.9M | Exercise | 1,699,753 | $1.69 | Discretionary |
Dongliang Lin currently holds 10,198,518 shares of CASI Pharmaceuticals, Inc. (CASI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Dongliang Lin has been a net neutral trader of CASI stock. They have purchased $0 and sold $0 worth of shares.
Dongliang Lin's most recent insider trade was on Nov 13, 2018, when they sold 1,699,753 shares at $1.69 per share.
Get notified when new Form 4 filings are submitted